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Cationic liposomes preferentially target tumor vasculature compared to vessels in normal tissues. The distribution of cationic liposomes along
vascular networks is, however, patchy and heterogeneous. To target vessels more uniformly we combined the electrostatic properties of cationic
liposomes with the strength of an external magnet. We report part I of development. We evaluated bilayer physical properties of our preparations.
We investigated interaction of liposomes with target cells including the role of PEG (polyethylene-glycol), and determined whether magnetic
cationic liposomes can respond to an external magnetic field. The inclusion of relatively high concentration of MAG-C (magnetite) at 2.5 mg/ml
significantly increased the size of cationic liposomes from 105±26.64 to 267±27.43 nm and reduced the zeta potential from 64.55±16.68 to
39.82±5.26 mv. The phase transition temperature of cationic liposomes (49.97±1.34 °C) reduced with inclusion of MAG-C (46.05±0.21 °C).
MAG-C cationic liposomes were internalized by melanoma (B16-F10 and HTB-72) and dermal endothelial (HMVEC-d) cells. PEG partially
shielded cationic charge potential of MAG-C cationic liposomes, reduced their ability to interact with target cells in vitro, and uptake by major
RES organs. Finally, application of external magnet enhanced tumor retention of magnetic cationic liposomes.
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More than 23% of all human deaths in the United States are
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hexatriene; DMEM, Dulbecco's Modified Eagle Medium; MEME, Eagles
Minimum Essential Medium; EBM-2, Endothelial Cell Basal Medium-2;
HMVEC-d, Human Dermal Microvascular Endothelial Cells; HMEC-1, Human
Dermal Microvascular Endothelial Cells; HUVEC, Human Umbilical Vein
Endothelial Cells; B16-F10, Murine melanoma; HTB-72, Human melanoma;
SRB, Sulforhodamine B
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doi:10.1016/j.bbamem.2006.10.006treatment strategies is therefore of vital importance, and is
urgently needed. A popular clinical approach targets functional
tumor vessels in an effort to destroy the existing tumor
vasculature. A common goal of all successful vascular targeting
strategies is the ability to interrupt the flow of oxygen and
nutrients to the developing tumor mass. Tumor vessels are the
main focus of this therapeutic approach, and cancer cells die as a
result of vascular injury [2].
One potential problem associated with the use of vascular
targeting strategies is the lack of specificity. For this reason,
the ability to reduce the total amount of drug delivered to
healthy tissues, while improving selective delivery to tumor
targets is a formidable challenge. Success with chemotherapy
is thus dependent on the correct identification of therapeutic
agents, as well as accurate identification and appropriate use
of strategies to deliver them to targets [3].
Another popular approach is magnetic drug targeting (MDT)
[4–6]. MDT improves selective delivery of chemotherapeutic
agents to tumors with the use of ferro fluids bound to drugs that
Table 1
Preparation of liposomal formulations
Group Liposome preparation Lipid ratio (mol%)
1 DMPC 100
2 DMPC/DMTAP 50:50
3 DMPC/DMTAP/CHOL 40:50:10
4 DMPC/DMTAP/CHOL/PEG 35:50:10:5
5 DMPC/DMTAP/CHOL/MAG-C 40:50:10
6 DMPC/DMTAP/CHOL/MAG-C/PEG 35:50:10:5
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strategy, the magnetic field retains the chemotherapeutic agent
at the intended site of drug action, and therefore increases drug
levels at this location. This minimizes the potential for
accumulation of drug in healthy tissues. Furthermore, the
combination of improved target selectivity, and enhanced
duration of drug exposure to target consequently reduce the
overall amount of drug taken up by the RES (reticuloendothe-
lial system) [5].
A prerequisite for any successful magnetic drug targeting
approach is that the ferro fluid–drug complex must reach the
tumor microcirculation and release the drug at this location
[8,9]. The most important parameters to be considered for
magnetic drug targeting are [5,10]: (1) the concentration,
and type of ferro fluid employed, (2) the magnetic strength
of the external magnetic field, (3) and the length of time the
target tissue is exposed to the external magnet. All three
parameters should be carefully selected and optimized for each
purpose.
A more recent contribution to the field of targeted drug
delivery involves the use of cationic liposomes [11–14].
Cationic liposomes, unlike their anionic and electroneutral
counterparts, have been shown to target tumor vessels to a
significant extent over vessels in normal healthy tissues,
targeting approximately 25 and 5% of vessel areas respectively
[14]. Although cationic liposomes preferentially accumulate in
tumors, the distribution of liposomes along tumor vessels is
non-uniform. Therefore, preferential sites of drug accumulation
are observed, and although many vessels are targeted some
vessel areas are not targeted by this approach.
We seek to develop one delivery vehicle that is (1) relatively
tumor specific, (2) capable of interacting with tumor vessels, (3)
and capable of responding to an external magnetic field.
Ultimately we hope to improve tumor vascular interactions with
cationic liposomes by forcing them to interact uniformly with
the tumor vasculature. By this approach we seek to overcome
the heterogeneity associated with the use of cationic liposomes
alone.
We report the first step of the development and characteriza-
tion of MAG-C (magnetite) cationic liposomes. We specifically
investigated the effect of MAG-C on bilayer physical properties
of cationic liposomes. We determined the extent to which they
associate with, and are internalized by, murine tumor (B16-
F10), human tumor (HTB-72), and Human Microvascular
Dermal Endothelial (HMVEC-d) cells in the presence and
absence of an external magnet. Lastly, we discuss the
implications of our in vitro and in vivo studies in terms of
tumor vascular targeting.
2. Experimental procedures
2.1. Materials
Dimyristoyl-phosphatidylcholine (DMPC), Dimyristoyl-trimethyl ammo-
nium propane (DMTAP), cholesterol, rhodamine-DPPE (N-Lissamine rhoda-
mine B sulfonyl)-dipalmitoyl-phosphatidylethanolamine) (Ammonium salt),
DMPE-PEG 5000 purchased from Avanti Polar Lipids (Alabaster, AL); fluid
MAG-C (aqueous dispersion of magnetite (Fe3O4) from Chemicell (Berlin,Germany); DPH (1, 6 diphenyl-1, 3, 5 hexatriene) purchased from Molecular
Probes (Eugene, OR, USA), permanent magnets were purchased from Master
Magnetics, Inc (Castle Rock, Colarado). For in vitro and in vivo experiments,
ceramic (0.4 T (Tesla) and neodymium (1.2 T) magnets were used,
respectively.
2.2. Cell culture and media
B16-F10 (CRL 6475) and SK-MEL-28 (HTB-72) cell lines were purchased
from ATCC (American Type Culture Collection, Manassas, VA). B16-F10 was
maintained in DMEM supplemented with 10% Fetal Bovine Serum (FBS). SK-
MEL-28 was cultured in MEME with 10% FBS. HMVEC-d (human dermal
microvascular endothelial cells) was maintained in EBM-2 with additional
required growth supplements both purchased from Cambrex Bio Science
(Walkersville, MD). All cell line cultures were grown in a humidified
atmosphere of 5% CO2 at 37 °C.
2.3. Preparation of liposomes
The components used to prepare liposomes were determined by the
experimental requirements. DMPC, DMTAP, cholesterol, and rhodamine-DPPE
represent the standard components used to prepare liposomes unless otherwise
stated. The required amount of lipid (typically around 10 μmol/ml) was
dissolved in chloroform, and then transferred to a pyrex tube (or round bottom
flask). The solvent in the tube was subsequently removed using a rotary
evaporator. The temperature was held slightly above the phase transition
temperature of the dominant lipid inmixture until a thin filmwas deposited on the
inside wall of the tube. The lipid film was then allowed to freeze-dry for 4 h. The
dried lipid film was hydrated with saline, different concentrations of MAG-C
(0.5 mg/ml, 2.5 mg/ml) in saline. The specific volume added to the dry film
depended on experimental purpose. The newly formed preparation was warmed
to a temperature slightly above the phase transition temperature of the dominant
lipid of preparation, and vortexed intermittently until the lipid film was
completely resuspended [15]. The composition of various liposomal formula-
tions is shown in Table 1. To produce a homogenous mixture of small
unilamellar vesicles, liposome preparations were sonicated in a bath type
sonicator (Laboratory Supplies Corporation, Hicksville, NY). Unincorporated
MAG-C was separated from the MAG-C associated variety by centrifugation at
1000×g for 15 min [16,17]. Determination of liposome size and zeta potential
was achieved with use of a 90 Plus Particle/ Zeta Potential Analyzer
(Brookhaven Instruments, Holtsville, NY).
2.4. Fluorescence polarization
The phase transition temperature (indicator of membrane fluidity) of
liposomes was calculated by the DPH fluorescence polarization method
discussed previously [18,19]. Briefly, DPH was dissolved in THF to give a
concentration of 1 mg/ml. The stock solution of liposomes (10 μmol/ ml) was
diluted to give a final concentration of 1 μmol/ml. Approximately 2 ml of diluted
liposome stock was mixed with 10 μl of DPH (1 mg/ml). The sample was
wrapped in aluminum foil and incubated at 37 °C for 30 min in an ISOTEMP
215 type water bath from Fisher Scientific (Pittsburgh, PA), and rigorously
vortexed in the absence of direct light. Fluorescence measurements were
performed using a scanning spectrofluorometer from Photon Technology
International (PTI) with a Peltier rapid temperature change element built into
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wavelength of 355 nm, emission wavelength of 430 nm, 4 nm of excitation and
emission slits, and FP110 film polarizers. Fluorescence polarization was
calculated using the following equation [19]:
P ¼ ½fl ð0; 0Þ  Gg  l ð0; 90Þ = ½fl ð0; 0Þ þ Gg  l ð0; 90Þg;
G ¼ l ð90; 0Þ = l ð90; 90Þ
Percent gel phase ¼ P=0:4 100
2.5. Cytotoxicity studies
The percent of cell viability was determined by sulforhodamine B assay
[20]. Cells were seeded at 1×104 cells/ml in each well of a 48 well plate (Fisher
Scientific, Pittsburgh, PA). Cells were allowed a sufficient amount of time to
adhere to well plate and cells were treated with different amounts of liposomes
(typically ranging from 10 to 1000 nmol). After 24 h, well plates containing cells
were washed with PBS to remove unbound liposomes and cellular debris. Cells
were fixed to plate by adding 100 μl of 50% TCA into each well followed by
storage at 4 °C for a 1 h period. After 1 h each well was washed 4 times with
distilled water and then cells were stained with 200 μl of 0.4% sulforhodamine B
for 30 min. To remove unbound stain, wells were washed with 1% acetic acid
and air-dried in a laminar flow hood [20,21]. Fluorescence intensity (FI) was
measured by dissolving bound sulforhodamine with 1 ml of 1× PBS at an
excitation wavelength of 550 nm, and emission wavelength of 590 nm using a
FLX 800 Fluorescence Microplate Reader, Bio-Tek Instruments Inc.,
(Winooski, Vermont). Percent of cell viability was calculated by the following
formula:
Percent of cell viability ¼ F:I: of treated cell population
F:I: of untreated cell population
 100
2.6. Cell–liposome interactions: quantitative analysis
To measure the extent of liposomes associated with cells, all cells were
seeded at 1×104 cells/ml in a 48 well plate. Cells were allowed to adhere to the
plate overnight and then various amounts of rhodamine labeled liposomes (10–
1000 nmol) were added. After 24 h the cells were washed with PBS to remove
unbound liposomes. The total fluorescence was measured by a FLX 800
Fluorescence Microplate Reader. Analysis of total rhodamine labeled liposome
uptake was determined as discussed in Cytotoxicity studies.
2.7. In vitro interaction of MAG-C liposomes in presence of external
magnet
To determine the influence of external magnet on the extent of association of
magnetic liposomes with murine melanoma and endothelial cells, cells were
seeded at 4×104 cells/ml in a 12 well plate. Cells were allowed to adhere to the
plate overnight and then rhodamine labeled magnetic cationic and electroneutral
liposomes (500 nmol) containing two different concentrations of MAG-C
(0.5 mg/ml and 2.5 mg/ml) were added to each well. Electroneutral liposomes
consisted of DMPC and cholesterol (50:50) and method of preparation is
described in Preparation of liposomes. A permanent magnet of strength 0.4 T
was placed under the cell culture plate for 1 h. For this period of 1 h the well
plate was placed on a Stovall Belly Dancer Shaker (Fisher Scientific, NJ) that
was set on slow and continuous rotation. After 1 h the plate was removed from
magnet and shaker. Following an additional 23 h incubator cells were
immediately washed with PBS to remove unbound liposomes. The total
fluorescence was measured by a FLX 800 Fluorescence Microplate Reader. The
percent association of magnetic liposomes with cells was calculated as discussed
in Cytotoxicity studies.
2.8. Fluorescence microscopy
Fluorescence microscopic analyses were carried out using a BX61 WI
Olympus fluorescence microscope fromOptical Analysis Corporation (Melville,
NY). Liposomes labeled with rhodamine-DPPE (N-Lissamine rhodamine Bsulfonyl)-dipalmitoyl-phosphatidylethanolamine) were used to investigate the
nature of liposome–cell interactions. Cells were seeded on sterile cover slips in 6
well plates at a density of 5×105 cells/ml. The cells were allowed to adhere on the
cover slips for 24 h in required growth medium. Cells were incubated for 24 h at
37 °C in a humidified atmosphere of 5% CO2. Cells were then exposed to
100 nmol of rhodamine labeled liposomes for 24 h following the initial
incubation period. Twenty-four hours later the required growth media was
removed, cells were washed with PBS to separate unbound liposomes from the
cellular-bound fraction. DIC (Differential Interference Contrast) microscopywas
used to observe cell shape and morphology prior to obtaining all fluorescence
images. Rhodamine channel was used to identify labeled liposomes in cells under
20× and 40× magnifications. DIC and fluorescence images were finally merged
or blended to observe association and/ or internalization of liposomes with
respect to the cell.
2.9. Biodistribution studies
Tissue distribution studies were performed in male SCID mice. B16-F10
cells were injected subcutaneously into male SCID mice between 8 and
10 weeks old. An average tumor volume of approximately 250 mm3 was
achieved 10 days post injection of cells. Approximately 0.1 ml of 111In labeled
MAG-C and PEGylated MAG-C cationic liposomes (20 μmol/ml) was
administered systemically via tail vein injection. Approximately 24 h post
injection the mice were anesthetized with isoflurane. Blood was collected from
the retro-orbital sinus. Mice were then sacrificed by cervical dislocation and
liver, lung, spleen and tumor were excised. The weight of each organ was
measured and the amount of radioactivity recovered by each organ was
determined with the use of Beckman Gamma 5500 B counter (Fullerton, CA).
Results were expressed as percent of injected dose per gram of tissue. Percent of
radioactivity in each organ was calculated as follows.
¼ CPM values in each organ=weight in gm
CPM values of injected dose
 100
2.10. In vivo tumor accumulation of MAG-C cationic liposomes in
presence of external magnet
B16-F10 cells were injected subcutaneously into SCID mice approximately
8–10 weeks old, and tumor was allowed to grow until tumor volume reached
250 mm3. B16-F10-bearing mice were divided into 4 groups. Group 1 and 3
received intravenous administration of MAG-C cationic liposomes without
application of an external magnet. Group 2 and 4 received injection of
preparation but tumor had access to externally applied (neodymium) magnet for
a period of 1 h. Mice in groups 1 and 2 were sacrificed immediately following
removal of magnet. Mice in group 3 and 4 were sacrificed and organs removed
1 h following the removal of magnet (or 2 h post-systemic injection of MAG-C
cationic liposomes). Tumor weight was measured and the amount of
radioactivity recovered was determined with a Beckman Gamma 5500 B
counter. Results were expressed as the percent of injected dose per gram of
tissue. Percent of radioactivity in each organ was calculated as per the equation
described above.
2.11. Statistical analysis
The non parametric Mann–Whitney U test was used to evaluate statistically
significant differences in the experimental groups. P values <0.05 were
considered statistically significant.
3. Results
3.1. Physicochemical characterization
Liposome size, charge, and membrane fluidity have
previously been shown to influence drug retention, intratumoral
distribution, and factors associated with the rate of elimination
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reason we investigated liposome size, zeta potential (surface
charge potential), and phase transition temperature of poten-
tially useful preparations. Several ingredients were used to
prepare MAG-C cationic liposomes. The extent to which each
component exerted its effect on bilayer physical properties was
determined (see Tables 1 and 2).
3.2. Liposome size
Changes in liposome size and dispersity are important
indicators of change in bilayer properties of liposomes. The
following values reported for liposome size were determined
following 10 min of sonication. The size of DMPC liposomes
(483±187.02 nm) tended toward smaller mean diameters when
the cationic lipid DMTAP was included as a component of the
preparation. However, this decrease was not statistically
significant (P>0.05). We also investigated the effect of
including cholesterol in DMPC/DMTAP preparations; choles-
terol significantly reduced liposome diameter of DMPC/
DMTAP liposomes from 369±144.38 nm to 105±26.64 nm.
When MAG-C (magnetite) was added at 0.5 mg/ml there was
no significant change in mean diameter of DMPC/DMTAP/
cholesterol liposomes, but higher MAG-C content (2.5 mg/ml)
resulted in a significant increase in mean diameter from 105±
26.64 nm to 267±27.43 nm.
3.3. Zeta potential
Quantitative changes in surface charge characteristics of
liposomes due to the inclusion of different liposome compo-
nents can be used to predict the relative affinity of tumor
vessels for liposomes on the basis of charge. Zeta potential
values were determined immediately following size measure-
ments, and were therefore the identical preparations used for
the determination of size. Zeta potential for electroneutral
liposomes consisting of DMPC alone was −0.26±3.99 mv.
This value increased significantly in the presence of 50 mol%
DMTAP (84.96±15.57 mv; P<0.05). The inclusion of
10 mol% cholesterol in DMPC/DMTAP preparations reduced
zeta potential from 84.96±15.57 to 64.55±16.68 (P>0.05). The
inclusion of 0.5 mg/ml of MAG-C into cationic liposomes
significantly reduced the zeta potential of MAG-C cationicTable 2
Physical characterization of liposomes: the size and zeta potential values for differ
sonication
Group Liposome preparation Size (nm) Zeta
1 DMPC 483±187.02 −0.26
2 DMPC/DMTAP 369±144.38 84.9
3 DMPC/DMTAP/CHOL 105±26.64 64.5
4 DMPC/DMTAP/CHOL/PEG 109±5.31 26.2
5 DMPC/DMTAP/CHOL/MAG-C (0.5 mg/ml) 142±27.40 43.7
6 DMPC/DMTAP/CHOL/MAG-C/PEG 141±14.52 21.9
7 DMPC/DMTAP/CHOL/MAG-C (2.5 mg/ml) 267±27.43 39.8
8 DMPC/DMTAP/CHOL/MAG-C/PEG 156±16.25 27.5
MAG-C containing liposomes were centrifuged at 1000×g for 15 min to remove unliposomes (43.79±10.93 mv) compared to preparations without
MAG-C (64.55±16.68mv). An increase inMAG-C (2.5mg/ml)
content resulted in no significant changes in zeta potential
compared to preparations containing 0.5 mg/ml of MAG-C.
3.4. Membrane fluidity
DPH (diphenylhexatriene) can be used to determine specific
changes in membrane fluidity due to components added to the
liposome preparation. The fluorescent membrane probe is
located deep within the core of the liposome bilayer, where it
can monitor changes in membrane phase behavior [26]. Due to
its specific location sudden changes in its rotational freedom can
be used to calculate the fraction of gel and liquid crystalline
phase at any given temperature [18,19,26]. We therefore used
DPH to investigate the fluidizing effect of MAG-C and various
lipids exerted on bilayer phase state.
Components used to investigate effects on size and zeta
potential were used here to investigate effects on membrane
fluidity. As with effects on size and zeta potential, each
liposome type represents the inclusion of one additional
component. For this reason, additional changes observed in
the rotational freedom of DPH in the bilayer will be used to
determine how each component alters bilayer phase state.
Fluorescence polarization values of approximately 0.45 and
0.0 correspond to 100% of gel and liquid crystalline phase of the
liposome bilayer, respectively. In liposomes of DMPC alone,
DPH had a polarization value of approximately 0.31 at 12 °C and
a phase transition temperature of 26 °C. The inclusion of
DMTAP (50 mol%) significantly increased the polarization
values to 0.45 at 12 °C. The phase transition temperature for
liposomes of DMPC/DMTAP was 42 °C. DMTAP therefore
reduced the fraction of liquid crystalline phase compared to
DMPC alone, as observed between temperatures of 12 to 45 °C.
After 45 °C DMPC and DMPC/DMTAP liposomes had similar
polarization values and existed predominately in the liquid
crystalline phase state (Fig. 1A). Incorporation of cholesterol
(10 mol%) increased the phase transition temperature of DMPC/
DMTAP liposomes from 42 °C to 50 °C. The bilayer properties
became more rigid in the presence of cholesterol compared to
liposomes of DMPC/DMTAP alone (Fig. 1B). Our data support
this conclusion showing that higher temperatures were required
to melt the lipid bilayer in the presence of cholesterol. The phaseent liposomal preparations were determined immediately following 10 min of
potential (mv) Group comparisons P values
Size Zeta potential
±3.99 – – –
6±15.57 1 and 2 NS P<0.05
5±16.68 2 and 3 P<0.01 NS
4±2.28 3 and 4 NS P<0.01
9±10.93 3 and 5 NS P=0.05
8±5.25 5 and 6 NS P<0.01
2±5.26 3 and 7; 5 and 7 P<0.05; P<0.05 P<0.05 NS
6±3.54 7 and 8 P<0.05 P<0.05
incorporated MAG-C.
Fig. 1. Fluorescence polarization (FP) as a function of temperature for magnetic
liposome preparations: DPH was incorporated into bilayers of different
liposomal formulations and fluorescence intensity values were recorded at
various temperatures at a fixed excitation and emission wavelength of 355 nm
and 430 nm respectively. FP values were plotted as a function of temperature for
each liposomal formulation and the values for FP were determined as discussed
in Experimetal procedures.
Fig. 3. Percent cell viability of melanoma and endothelial cells treated with
MAG-C cationic liposomes: Cells were seeded at 1×104 cells/ml in a 48 well
plate and incubated at 37 °C. Percent of cell viability was determined following
24 h of exposure to various amounts of magnetic cationic liposomes (10–
1000 nmol). Percent cell viability was calculated for each liposome
concentration based on the formula provided in Experimetal procedures. The
control group was untreated. Each value represents the mean±S.D. of 7 different
experimental determinations (*P<0.05 and #P<0.01 compared to 10 nmol).
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the inclusion of low concentrations ofMAG-C (0.5 mg/ml) (Fig.
2). As the MAG-C concentration was increased to 2.5 mg/ml the
phase transition temperature decreased from 50 °C to 46 °C.
3.5. Cell viability assay
We evaluated the effect of MAG-C cationic liposomes on cell
viability. We observed no toxic effects on cell growth against
murine melanoma (B16-F10), human melanoma (HTB-72), and
human dermal microvascular endothelial (HMVEC-d) cells atFig. 2. Phase transition temperature of different liposomal formulations. Based
on the polarization values, percent gel phase was calculated as described in
Experimetal procedures.<1000 nmol (Fig. 3). The percent of viable B16-F10, HTB-72
and HMVEC-d cells after 24 h exposure to 500 nmol of
liposomes was 92, 85, and 78% respectively (Fig. 3). Although
the values reported here for HMVEC-d tended toward relatively
lower cell viabilities, no statistically significant effects were
observed. The percent of viable cells remaining in culture after
exposure to MAG-C cationic liposomes reduced significantly at
≥500 nmol compared to 10 nmol with all three cell lines.
Moreover, we observed no significant difference in cell viability
among cell lines at any given concentration, suggesting that the
liposomes were equally toxic to both cancer and microvascular
endothelial cells.
3.6. Cell association studies
The tendency of MAG-C cationic liposomes to associate
with cells increased with liposome amount, and association
values were similar for the three cell lines. We observed no
significant increase in cell association >500 nmol of liposomes
(Fig. 4).Fig. 4. Association of MAG-C cationic liposomes with melanoma and
endothelial cells in vitro: Cells were seeded at 1×104 cells/ml in a 48 well
plate and incubated at 37 °C. The relative association of cells with each liposome
preparation type was determined 24 h following cell exposure to rhodamine
labeled liposomes (10–1000 nmol). The control group was untreated. Each
value represents the mean±S.D. of 6 different determinations.
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liposomes we used DIC and fluorescence microscopic metho-
dology. Images were acquired with the use of each technique,
and were merged to assess site(s) of accumulation relative to
cellular organelles (Fig. 5B). Avid accumulation of MAG-C
cationic liposomes was evident in all cell lines with the most
significant uptake observed in B16-F10 andHTB-72. In addition
we note perinuclear uptake in HMVEC-d cells.
3.7. Role of PEG in MAG-C cationic liposomes
A sterically stabilized liposome is one that is surface coated
with polyethylene glycol (PEG), or some other polymer [27].
The purpose of including PEG in preparations is to limit theFig. 5. Analysis of MAG-C association with liposomes: Liposomes were prepa
microscopy and RGB. (A) Incorporation of MAG-C in cationic liposomes: (i) cation
MAG-C cationic liposomes under RGB filter (100×), (iii) DIC image of MAG-C c
indicate MAG-C. (B) Intracellular uptake of MAG-C cationic liposomes: Cells were
labeled MAG-C cationic liposomes for 24 h at 37 °C with 100 nmol of liposom
blended image of fluorescence and DIC show the localization of MAG-C in cells. M
was 40×.interaction of liposomes with opsonins in blood; acquisition to
proteins in blood rapidly eliminates them from systemic
circulation [25]. Liposomes bearing a high cationic surface
charge potential are the most sensitive to this mechanism of
elimination, and so our MAG-C cationic liposomes could suffer
a similar fate. Prolonging the circulation half-life of MAG-C
cationic liposomes should increase overall tumor vascular
targeting efficiency due to extended access to the external
magnetic field. We therefore investigated the effect of PEG on
bilayer physical properties.
We determined the effect of 5 mol%DMPE-PEG on size, and
zeta potential, of cationic liposomes containing MAG-C. The
following studies compared MAG-C cationic liposomes to
MAG-C PEGylated cationic liposomes (MAG-C PCLs). Thered as discussed in Experimetal procedures. Images were acquired by DIC
ic liposomes (DMPC/DMTAP/cholesterol) under DIC (40×), (ii) DIC image of
ationic liposomes taken up by B16-F10 cells under RGB filter (40×). Arrows
seeded at 5×105 cells/ml in a 6 well plate. Cells were treated with rhodamine
es. Rhodamine labeled MAG-C cationic liposomes are indicated in red. The
agnification setting for B16-F10 and HTB-72 was 20×, and for HMVEC-d it
Fig. 7. In vivo tissue distribution profile of 111In labeled MAG-C cationic and
PEGylated MAG-C cationic liposomes in mice bearing subcutaneous melanoma
tumors of approximately 250 mm3 volume. Mice were injected with 111In
labeled liposomes. 1—MAG-C cationic liposomes, 2—PEGylated MAG-C
cationic liposomes. Twenty-four hours post injection of each preparation type,
percent of label recovered by liver, lung, spleen, blood and tumor was
determined. Each value represents mean±S.D. of 4 animals per group, P<0.05.
Fig. 6. Cell association—comparison of MAG-C cationic liposomes versus
PEGylated cationic liposomes (PCLs) containing MAG-C: cells were seeded at
1×104 cells/ml in a 48 well plate and incubated at 37 °C. Association
measurements were determined 24 h following exposure of cells to various
amounts of rhodamine labeled MAG-C cationic liposomes, and MAG-C
PEGylated cationic liposomes (10–1000 nmol). The control group was
untreated. MAG-C PEGylated cationic liposomes interacted with all three cell
lines to a significantly less extent compared to MAG-C cationic liposomes
without the inclusion of PEG. Each value represents the mean±S.D. of 3 sets of
determination, P<0.01. (A) B16-F10 cells, (B) HTB-72, (C) HUVEC.
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14.22 and was similar to values reported for MAG-C
liposomes in absence of PEG (141.143±31.55). PEG
reduced zeta potential of cationic liposomes containing
MAG-C, showing a value of 21.98±5.25 mv compared to
preparations without PEG (43.79±10.93 mv). The inclusion
of DMPE-PEG to the cationic liposome preparation contain-
ing relatively high MAG-C (2.5 mg/ml) content resulted in a
significant decrease in liposome size from 262.67±27.43 to
156±16.25 nm.
We next compared the interaction of PCLs with cancer (B16-
F10 and HTB-72) and endothelial (HUVEC) cell lines. Weobserved that the inclusion of PEG significantly reduced cellular
interactions regardless of cell type (Fig. 6).
These data suggest that the inclusion of 5 mol% PEG altered
bilayer physical properties such as liposome cationic surface
charge potential, but did not affect liposome size. Finally, PEG
limited the association of MAG-C cationic liposomes with all
cell lines; reduced interactions may be due to the reported
decrease in zeta potential (P<0.01).
3.8. In vivo tissue distribution profile of 111In labeled MAG-C
cationic and PEGylated MAG-C cationic liposomes
We next determined the effect of PEG on tissue distribution
profile of MAG-C cationic liposomes in melanoma bearing
SCID mice. When MAG-C cationic liposomes were injected
intravenously into melanoma bearing mice, the percent of
injected dose per gram of the tissue in lung, liver and spleen was
35.27, 56.61 and 75.92% respectively (Fig. 7). The inclusion of
5 mol% DMPE-PEG resulted in a significant reduction in the
uptake by the major organs of RES. The significant reduction
was due to the electrostatic repulsive effect of PEG [25,27].
Moreover, tumor/blood ratio for PEGylated MAG-C cationic
liposomes (4.36±1.14) was significantly higher than that for
MAG-C cationic liposomes (1.56±0.43). The data suggest that
PEG minimizes uptake of MAG-C cationic liposomes by
healthy tissues while improving tumor uptake.
3.9. Cellular interactions of MAG-C liposomes in presence of
magnet
We have noted that MAG-C can be successfully incorporated
in cationic liposomes however, whether or not the concentration
is sufficiently available in liposomes to respond to an external
magnet has yet to be established. For this reason, cellular
interaction of MAG-C liposomes was studied in the presence
and absence of an external magnet in vitro. From the cell
association studies of MAG-C liposomes with B16-F10 and
HMEC-1 cells we observed that there was no significant
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Fig. 9. Effect of external magnetic field on tumor distribution of MAG-C
cationic liposomes. Approximately 2×106 B16-F10 cells were injected
subcutaneously in mice bearing melanoma tumors of approximately 250 mm3
volume. Mice were injected with 111In labeled MAG-C cationic liposomes and
external magnet of strength 1.2 T was placed for 1 h on the external surface of
tumor mass. After 1 and 2 h post injection, radioactivity in tumor was measured;
data are expressed as percent of label recovered per/ gram of tumor (see
Experimetal procedures). Each value represents mean±S.D. of 4 animals,
P<0.05.
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the minimal amount of toxicity associated with the use of this
amount was acceptable. We therefore compared the cell
association of MAG-C liposomes (500 nmol) in presence and
absence of an external magnet (0.4 T).
The association of MAG-C PCLs (containing 0.5 mg/ml of
MAG-C) with B16-F10 cells without the external magnet was
16±1.19% and was similar to interaction in presence of
magnet (17±1.17%) (Fig. 8). We also noted no significant
benefit of using the external magnet at 2.5 mg/ml of MAG-C.
The ability of cationic liposomes to be internalized by cells in
absence of magnet may have overshadowed the benefit of using
the external magnet under the current experimental setup. We
therefore evaluated the ability of MAG-C electroneutral
liposomes (containing 0.5 mg/ml of MAG-C) to associated
with B16-F10 cells in presence of the external magnet. The result
was 4.78±0.8% which was similar to when cells were exposed
to electroneutral liposomes without the magnet. We however
observed an approximate 2 fold significant increase in associa-
tion of MAG-C electroneutral liposomes from 4.55±1.28% to
7.25±0.19% with the external magnet at 2.5 mg/ml MAG-C.
We next carried out the same study using human dermal
endothelial cells, our in vitro model of capillary networks. The
interaction of MAG-C PCLs (20±6%) to the vascular cells in
the presence of the magnet was however similar to without
magnet (25±6.5%). Similar to B16-F10 studies, the association
of MAG-C electroneutral liposomes (with 2.5 mg/ml of MAG-
C) significantly increased from 8.8±1.87% to 20.18±0.51% in
presence of external magnet (Fig. 8).
3.10. Tumor accumulation of MAG-C cationic liposomes in
presence of external magnet
In this study we examined the effect of the external magnet
(1.2 T) on biodistribution of MAG-C cationic liposomes in B16-
F10 melanoma bearing mice. First, the external magnet was
placed on the external surface of the tumor followed by systemic
injection of 111In labeled MAG-C cationic liposomes. The
magnet remained associated with the tumor mass for 1 h. The
percent of label recovered by the tumor following exposure to
external magnet was compared to the (unexposed) control
group. At the 1 h time point we observed no significant
difference between the two groups, as determined by the similar
percent of label recovered by tumors in the presence (4.2±1.08)
and absence (4.71±0.4) of magnet (Fig. 9). We however, did
observe a significant difference at the 2 h time point (or 1 h
following the removal of magnet). At this time interval tumors
with no previous exposure to external magnet retained
significantly less of the label, compared to tumors previously
exposed to magnet (P<0.05; Fig. 9). Percent of label recovered
by tumor in absence and presence of external magnet at 2 h time
point was (5.04±0.73) and (3.3±0.54) respectively.Fig. 8. Association of magnetic liposomes with melanoma and endothelial cells in pres
4×104 cells/ml in a 12 well plate and incubated at 37 °C. The percent association o
exposure to rhodamine labeledMAG-CPCLs andMAG-C electroneutral liposomes (5
of 4 different determinations. (A) B16-F10, (B) HMEC-1.The experimental findings suggest that the external magnet
significantly enhanced tumor retention and facilitated vascular
uptake of MAG-C cationic liposomes. Enhanced tumor
vascular association is the preferred mechanism of uptake
given the natural affinity of cationic liposomes for tumor
vessels [13,14,28].
4. Discussion
The systemic administration of chemotherapeutic agents is a
popular treatment approach used to control local tumor growth
and distant metastasis, but not without some controversy. Today,
there is an urgent need to reduce drug-associated side effects
while preserving the efficacious nature of all chemotherapeutic
agents. The field of nanotechnology hasmade remarkable strides
in this direction. For example, the attachment of surface bound
polymers (i.e., PEG) provide adequate protection of liposomes
from unfavorable interactions with insoluble proteins in blood;
such interactions alter tissue distribution and tumor-specific
uptake [25,27].
In general, relatively long circulating liposomes result in
enhanced delivery of drugs to solid tumors; however, the
inclusion of PEG in preparations alone will not promote
vascular-specific uptake in tumors. Earlier studies with
cationic liposomes confirmed organ-specific uptake and
preferential accumulation in tumors, specifically along tumor
angiogenic vessels [13,28]. In order to preserve both the well-
established benefits of PEG and the natural attraction of
cationic liposomes for tumor vessels, PEG-modified cationic
liposomes (PCLs) were evaluated in vivo [14]. Studies
revealed preferential tumor vascular uptake but the distribution
was non-uniform [14].ence of external magnet (0.4 T, exposure time—1 h) in vitro: Cells were seeded at
f cells with each liposome preparation type was determined 24 h following cell
00 nmol). The control groupwas untreated. Each value represents themean±S.D.
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relatively tumor vascular-specific liposomes capable of respond-
ing to an external magnet. A potential candidate must
demonstrate the ability to incorporate magnetic materials,
maintain a mean diameter of around 150 nm, preserve a cationic
charge potential, and avidly associate with human cancer and
endothelial cells in vitro and in vivo.
We also investigated the role of PEG in our MAG-C cationic
liposomes. The goal here was to develop relatively long
circulating cationic liposomes that would permit additional time
(if needed) for liposomes to respond to an externally applied
magnet. All together, we report on the development and
characterization of different components of bilayer physical
properties of magnetic cationic liposomes. We determined the
overall benefit of applying an external magnet. This was first
accomplished by studying the interaction of magnetic cationic
liposomes with melanoma and immortalized endothelial cells,
serving as in vitro models of the interstitial and vascular
compartments respectively. Our investigations represent the
very first step in the development process.
In the first phase of our studies we evaluated the effect of
various components on (i) liposome size, (ii) surface charge
density, and (iii) membrane fluidity. The inclusion of 50 mol%
DMTAP in DMPC preparations reduced the mean diameter of
liposomes; but, the apparent reduction in size was not significant
(P>0.05). The inclusion of cholesterol (10 mol%) in DMPC/
DMTAP (1:1) mixtures did however reduce the mean diameter
to a significant extent. Upon visual inspection of stock
preparations cholesterol appeared to also eliminate unwanted
liposome aggregates, resulting in a more homogenous stock
preparation compared to DMPC/DMTAP alone. The ability to
alter bilayer fluid dynamics, and increase bilayer stability are
additional known effects of cholesterol [15]. In a previously
reported study the effect of the inclusion of DOTAP (50 mol%)
on liposome size of DMPC liposomes was investigated [18].
Computational studies carried out by Zuidam and Barenholz
with DOPC/DOTAP (1:1) mixtures showed that both the
quaternary amine of DOTAP and the phosphate group of
DOPC are oriented in the same plane of the bilayer relative to the
glycerol backbone [29]. In this arrangement the formation of a
salt bridge might assist in the reduction of liposome size, in
addition to exerting additional physical effects [18]. Our studies
are consistent with the experimental and computational findings
of these reports. We therefore speculate that the significant
reduction in mean diameter of DMPC/DMTAP preparations in
the presence of 10 mol% cholesterol was due to cholesterol's
ability to elimination liposome aggregates, and DMTAP's
ability to promote interactions between head group moieties of
DMPC and DMTAP. When MAG-C (0.5 mg/ml) was included
as part of the DMPC/ DMTAP/cholesterol preparation, we
observed no additional change in size, however, an increase in
MAG-C content (from 0.5 to 2.5 mg/ml) did increase liposome
size (P<0.05).
The second bilayer property investigated (also critical to
overcoming tumor vascular heterogeneity) was the effect of
each component on cationic charge potential. Although
cationic liposomes preferentially target the tumor endothe-lium, 50 mol% cationic lipid content was significantly more
effective than 10 mol% [14]. Given that relatively high
cationic charge density is necessary to achieve optimal
vascular targeting efficiency, we determined to what extent
each of our magnetic liposome components influence cationic
charge potential.
The inclusion of 50 mol% DMTAP to DMPC liposomes was
found to increase zeta potential values significantly. When
MAG-Cwas added, the zeta potential value for DMPC/DMTAP/
cholesterol preparations was significantly lower compared to
same lipid composition without MAG-C. Given that the
inclusion of MAG-C significantly reduced zeta potential of
DMPC/DMTAP/cholesterol liposomes, its ability to alter bilayer
properties involving surface charge is primarily due to the
anionic charge of fluid MAG-C (−35 mv). In addition, MAG-C
might well interact with the quaternary amine group of DMTAP,
since DMPC and cholesterol are electroneutral and do not
possess characteristics sufficient to shield a cationic charge
density whether alone, or when used in combination. The
findings suggest that MAG-C interacts with the (cationic) polar
head group region of the bilayer, where it neutralizes some of the
positive surface charge characteristics due to charge shielding.
Zeta potential values for PCLs used to target tumor vessels were
previously reported between 20 to 25 mv [14], suggesting that
our values reported here for magnetic cationic liposomes are
sufficient.The final bilayer property investigated involved
effects on bilayer fluid dynamics. DPH polarization is a widely
accepted method used to monitor changes in bilayer phase state
due to the inclusion of various membrane constituents [19, 30].
DPH was used to determine how each liposome component
exerts an effect on membrane fluidity. The phase transition
temperature of DMPC liposomes was 26 °C; our findings were
similar to values reported elsewhere [31,32]. The inclusion of
DMTAP increased the phase transition temperature of DMPC
liposomes from 26 to 42 °C, a significant increase in the fraction
of liposome gel phase state. The addition of cholesterol further
increased the phase transition temperature of DMPC/DMTAP
liposomes, resulting in a bilayer that was apparently more rigid
with considerably less acyl chain mobility. The phase transition
temperature of DMPC/DMTAP/ cholesterol/MAG-C (0.5 mg/
ml) liposomes was similar to cationic liposomes suggesting that
MAG-C did not alter the bilayer physical properties at this
concentration. However, MAG-C at a higher concentration
(2.5 mg/ml) lowered the fluorescence polarization values of
DMPC/DMTAP/cholesterol liposomes. So the overall extent to
which MAG-C exerts an effect on liposome bilayer structure
appears to be concentration dependent. Given the anionic charge
potential (−35 mv) of MAG-C and the extent to which it exerts
an effect on membrane fluidity, the sum of these interactions is
probably not limited to the membrane interfacial region.
Interactions may extend to include saturated acyl chains of
DMPC and DMTAP as well.
Our analysis of DPH polarization studies, including the
potent effect of MAG-C on cationic charge potential, is further
supported by our data demonstrating the direct association of
MAG-C with cationic liposome membranes (Fig. 4A, ii). The
data also show that the presence of MAG-C in the liposome
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internalizing cationic liposomes (Fig. 4A, iii).
Sulforhodamine B (SRB) assay is a method used to evaluate
drug-induced cytotoxic effects in vitro [20]. SRB is a bright
pink aminoxanthene dye used to stain basic proteins of viable
cells. The successful staining of cellular proteins is a frequently
used indicator of cellular viability [20]. We used the SRB assay
to determine relative effect of different amounts of MAG-C
cationic liposomes on murine (B16-F10) and human (HTB-72)
melanoma, and human dermal endothelial (HMVEC-d) cells in
vitro. We observed that <1 μmol of magnetic cationic liposomes
was a suitable working concentration range, above which
significant cell death was observed (data not shown).
We evaluated the interaction of magnetic cationic liposomes
with B16-F10, HTB-72 and HMVEC-d cells both quantitatively
and qualitatively. Our quantitative analysis of cultured cells
revealed similar interactions of MAG-C cationic liposomes with
B16-F10, HTB-72 and HMVEC-d.
We next determined the effect of 5% DMPE-PEG on the
bilayer physical properties of magnetic cationic liposomes. We
observed that the inclusion of PEG exerted no additional effects
on liposome size (containing low MAG-C content), but
significantly reduced zeta potential (P<0.01). However,
DMPE-PEG significantly reduced liposome size (when rela-
tively high MAG-C content was included). The reduction may
be due to the stabilizing effect of PEG [33,34].
PEG reduced interaction of MAG-C preparations with all
three cell lines. The polymer will reduce liposome uptake by the
RES, but the extended circulation time provided by PEG in vivo
may also improve overall tumor vascular uptake so long as the
external magnet is applied. The interaction between cancer and
endothelial cells with magnetic cationic liposomes was similar.
Given the high affinity of tumor vessels for cationic liposomes
and that tumor vessel have much greater access to systemically
administered formulations, using magnetic PCLs for tumor
vascular targeting (over interstitial delivery) is preferred.
When human endothelial cells were exposed to MAG-C
cationic liposomes we observed no significant advantage of
using the external magnet in vitro. We hypothesized that the
naturally high affinity of mammalian cells for cationic
liposomes (without the magnet) was responsible for the
apparent lack of benefit. To confirm this hypothesis we used a
low cellular binding electroneutral liposome variety to deter-
mine if the advantage of applying the external magnet could be
observed under these conditions. We observed a significant
increase in cell association in the presence of the magnet when
2.5 mg/ml of MAG-C was used, but not with 0.5 mg/ml. The
avid electrostatic interactions initially observed between
endothelial cells and MAG-C cationic liposomes were therefore
responsible for the lack of benefit. More importantly, the
amount of MAG-C included in liposome preparations will
likely determine how well magnetic carriers respond to an
external magnet.
In vitro screening of potentially useful magnetic formulations
is both a time-sensitive and cost effective approach however,
optimization may be necessary to achieve desired results. In
addition to natural cell attractions in absence of magnet, otherfactors to consider are cell seed number and liposome amount.
Although we observed no benefit of using magnetic cationic
liposomes in vitro, we did however observe a benefit in vivo.
Our experimental findings now support the use of MAG-C
cationic liposomes as a carrier for the delivery and prolonged
tumor accumulation of chemotherapeutic agents in the presence
of an external magnetic field.
The use of magnetic liposomes has been demonstrated for
various applications [4,7,10,17,35,36]. Nobuto et al., showed
that administration of magnetic DOX liposomes with subse-
quent application of magnetic field (0.4 T) produced a 3 to 4 fold
higher doxorubicin concentration in tumors of osteosarcoma
bearing hamsters, compared to magnetic DOX liposomes
without external magnet [17]. Zhang et al., extended the
circulation half life of paclitaxel and decreased uptake by RES
with the administration of lyophilized paclitaxel magneto
liposomes also under the influence of external magnet [4].
In conclusion, our data suggest that MAG-C cationic
liposomes satisfy an important set of criteria. Our liposomes
can incorporate MAG-C, maintain a cationic charge potential in
presence of magnetic material, are taken up by cancer and
endothelial cells, and under certain conditions can respond to an
external magnet in vitro and in vivo. These characteristics are
necessary to overcome heterogeneous vascular targeting with
cationic liposomes when used to induce tumor vascular injury
with vascular disrupting agents. For this reason subsequent in
vivo investigations are warranted.
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